Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)

被引：0
|
作者：
Kortuem, M. [1 ]
Terpos, E. [2 ]
Badros, A. [3 ]
Popat, R. [4 ]
Rodriguez-Otero, P. [5 ]
Farooq, A. [6 ]
Jeng, B. [3 ]
Esposti, Degli S. [7 ,8 ]
Lewis, E. [9 ]
Gupta, I [10 ]
Opalinska, J. [10 ]
Palumbo, A. [11 ]
Trudel, S. [12 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[4] Univ Coll London Hosp, NHS Fdn Trust, London, England
[5] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[8] UCL Inst Ophthalmol, London, England
[9] GlaxoSmithKline, Res Triangle Pk, NC USA
[10] GlaxoSmithKline, Upper Providence, PA USA
[11] GlaxoSmithKline, Zug, Switzerland
[12] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep211
引用
收藏
页码：204 / 204
页数：1
相关论文
共 30 条
  • [21] Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin
    Popat, Rakesh
    Badros, Ashraf Z.
    Kumar, Shaji
    Rodríguez-Otero, Paula
    Cohen, Adam D.
    Manier, Salomon
    Voorhees, Peter M.
    Gay, Francesca
    Rifkin, Robert M.
    Martin, Thomas
    Chari, Ajai
    Weisel, Katja
    Farooq, Asim V.
    Jeng, Bennie H.
    Chng, Wee Joo
    Lee, Hans C.
    Berdeja, Jesus
    Jadhav, Vinay
    Tosolini, Alessandra
    Eliason, Laurie
    Palumbo, Antonio
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Trudel, Suzanne
    Richardson, Paul G.
    Terpos, Evangelos
    BLOOD, 2021, 138
  • [22] METHODOLOGY FOR EVALUATING MEANINGFUL CHANGE THRESHOLDS IN PATIENT-REPORTED OUTCOME (PRO) MEASURES FOR CORNEAL EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF)
    Eliason, L.
    Loubert, A.
    Gorsh, B.
    Meunier, J.
    Kleinman, D.
    Sapra, S.
    Regnault, A.
    VALUE IN HEALTH, 2020, 23 : S477 - S477
  • [23] DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
    Trudel, S.
    Nooka, A.
    Fecteau, D.
    Talekar, M.
    Jewell, R. C.
    Williams, D.
    Evans, J.
    Opalinska, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
    Lonial, Sagar
    Lee, Hans Chulhee
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola A.
    Callander, Natalie Scott
    Sborov, Douglas Weston
    Suvannasankha, Attaya
    Weisel, Katja
    Voorhees, Peter Michael
    Hoos, Axel
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Jewell, Roxanne C.
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Pivotal DREAMM-2 Study: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) refractory to Proteasome Inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 Monoclonal Antibodies (mAbs)
    Weisel, K.
    Lonial, S.
    Lee, H. C.
    Badros, A.
    Trudel, S.
    Nooka, A. K.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P. M.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R. C.
    Opalinska, J.
    Gupta, I
    Cohen, A. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 102 - 103
  • [26] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
  • [27] Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
    Popat, Rakesh
    Warcel, Dana
    O'Nions, Jenny
    Cowley, Anna
    Smith, Sasha
    Tucker, William R.
    Yong, Kwee
    Esposti, Simona Degli
    HAEMATOLOGICA, 2020, 105 (05) : E261 - E263
  • [28] Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics
    Lonial, Sagar
    Lee, Hans Chulhee
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie Scott
    Sborov, Douglas Weston
    Suvannasankha, Attaya
    Weisel, Katja
    Voorhees, Peter M.
    Hultcrantz, Malin
    Libby, Edward N.
    Richardson, Paul G.
    Otero, Paula Rodriguez
    Besemer, Britta
    Facon, Thierry
    Hoos, Axel
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Jewell, Roxanne C.
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S301 - S302
  • [29] Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, Katja
    Hopkins, Thomas G.
    Fecteau, Doug
    Bao, Weichao
    Quigley, Corinne
    Jewell, Roxanne C.
    Nichols, Maureen
    Opalinska, Joanna
    BLOOD, 2019, 134
  • [30] Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    BLOOD, 2020, 136
123